

Appendix A

Claim Amendments

10/507500

DT04 Rec'd PCT/PTO 13 SEP 2004

1. (Currently amended) Use of A method of treating an airway disorder in a patient comprising administering to a patient in need thereof a therapeutically effective amount of a proton pump inhibitors in the treatment of airway disorders inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt or solvate of a salt thereof.
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Original) Ready-to-use medicament comprising a proton pump inhibitor as active compound and a reference to the fact that it can be employed for the treatment of airway disorders.

7. (Currently amended) The method of claim 1 ~~Proton pump inhibitor as mentioned in any of Claims 1 to 6,~~ characterized in that it is a compound wherein the proton pump inhibitor is selected from the group consisting of 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: omeprazole), 5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphonyl]-1H-benzimidazole (INN: esomeprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: lansoprazole), [[and]] 2-[(4-(3-methoxypropoxy)-2-methylpyridin-2-yl)methylsulphonyl]-1H-benzimidazole (INN: rabeprazole), ~~and in particular 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: pantoprazole),~~ [[and]] (-)-5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphonyl]-1H-benzimidazole (INN: (-)-pantoprazole) and a pharmaceutically acceptable salt, hydrate, solvate, hydrate of a salt or solvate of a salt thereof ~~their pharmacologically acceptable salts.~~

8. (Currently amended) The method of claim 1, wherein the
proton pump inhibitor ~~Proton pump inhibitor~~ as
~~mentioned in any of claims 1 to 6, characterized in~~
~~that it is pantoprazole or a pharmacologically~~
~~acceptable salt~~ pharmaceutically acceptable salt,
hydrate, solvate, hydrate of a salt or solvate of a
salt thereof.
9. (Currently amended) The method of claim 1, wherein the
airway ~~Airway disorder as mentioned in any of Claims 1~~
~~to 6, characterized in that it is~~ selected from the
group consisting of bronchitis, COPD, asthma,
pneumonitis ~~[[or]]~~ and pulmonary fibrosis.
10. (New) The method of claim 1, wherein the proton pump
inhibitor is selected from the group consisting of
pantoprazole sodium sesquihydrate, (-)-pantoprazole
sodium sesquihydrate, pantoprazole magnesium
dihydrate, omeprazole-magnesium, omeprazole-magnesium
tetrahydrate, esomeprazole-magnesium and esomeprazole-
magnesium tetrahydrate.